Mesoblast (MESO)
NASDAQ:MESO
Want to see MESO full AI Analyst Report?
MESO Stock Chart & Stats
$16.46
-$0.53(-2.96%)
At close: 4:00 PM EST
$16.46
-$0.53(-2.96%)
Day’s Range― - ―
52-Week Range$9.88 - $21.50
Previous CloseN/A
Volume155.35K
Average Volume (3M)168.51K
Market Cap
$1.90B
Enterprise Value$1.99B
Total Cash (Recent Filing)$161.16M
Total Debt (Recent Filing)$128.16M
Price to Earnings (P/E)―
Beta1.50
Next Earnings
Sep 02, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding129,156,280
10 Day Avg. Volume177,312
30 Day Avg. Volume168,514
Financial Highlights & Ratios
PEG Ratio2.44
Price to Book (P/B)2.20
Price to Sales (P/S)76.48
P/FCF Ratio-25.95
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue115.93
Enterprise Value/Gross Profit-55.60
Enterprise Value/Ebitda-34.27
Forecast
1Y Price Target
$35.00Price Target Upside112.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$125.51M
Bulls Say, Bears Say
Bulls Say
Market Access & Payer CoverageBroad, durable reimbursement and coding (J‑code) plus wide payer coverage reduce billing friction and support sustained uptake. This structural access lowers adoption barriers, enabling repeatable revenue from hospital networks and payers over the next 2–6 months as sales scale.
High Gross Margins And Revenue TrajectoryVery high product gross margin indicates strong unit economics for Ryoncil, supporting durable cash generation as volumes grow. Coupled with clear FY26 Ryoncil revenue guidance, these margins create sustainable operating leverage as commercialization expands.
Solid Liquidity & Nondilutive FinancingSubstantial cash plus a nondilutive facility materially improves runway and reduces near-term dilution risk. This financing flexibility supports commercialization, regulatory filings and manufacturing scale-up while subordinated royalty repayment is managed through mid‑2026.
Bears Say
Revenue Concentration RiskNearly all revenue comes from one newly launched product, creating structural concentration risk. Any setbacks—slower adoption, reimbursement changes, supply issues or competition—would materially affect cash generation and corporate outlook until pipeline diversifies revenue.
Negative Operating Cash FlowThe company continues to consume operating cash (H1 operating cash use ≈ $30.3M) and post net losses, requiring ongoing financing or facility draws. Persistent negative operating cash flow pressures liquidity and raises execution risk if commercial ramp or milestone receipts slow.
Rising R&D And SG&A From Scale-upSharp increases in R&D and commercialization costs strain margins and cash as the company scales. Elevated spend is necessary for trials, filings and market development, but it lengthens the path to break‑even and makes near‑term cash planning sensitive to execution and reimbursement outcomes.
Mesoblast News
MESO FAQ
What was Mesoblast’s price range in the past 12 months?
Mesoblast lowest stock price was $9.88 and its highest was $21.50 in the past 12 months.
What is Mesoblast’s market cap?
Mesoblast’s market cap is $1.90B.
When is Mesoblast’s upcoming earnings report date?
Mesoblast’s upcoming earnings report date is Sep 02, 2026 which is in 91 days.
How were Mesoblast’s earnings last quarter?
Mesoblast released its earnings results on Feb 25, 2026. The company reported -$0.311 earnings per share for the quarter, missing the consensus estimate of -$0.07 by -$0.241.
Is Mesoblast overvalued?
According to Wall Street analysts Mesoblast’s price is currently Undervalued.
Does Mesoblast pay dividends?
Mesoblast does not currently pay dividends.
What is Mesoblast’s EPS estimate?
Mesoblast’s EPS estimate is 0.
How many shares outstanding does Mesoblast have?
Mesoblast has 129,156,280 shares outstanding.
What happened to Mesoblast’s price movement after its last earnings report?
Mesoblast reported an EPS of -$0.311 in its last earnings report, missing expectations of -$0.07. Following the earnings report the stock price went up 0.059%.
Which hedge fund is a major shareholder of Mesoblast?
Currently, no hedge funds are holding shares in MESO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesoblast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (112.64% Upside)
$35.00 (112.64% Upside)
Blogger Sentiment
Bullish
MESO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 12.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $37.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 10.1%
Last 30 Days ▼ 10.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
39.66%
12-Months-Change
Fundamentals
Return on Equity
-14.02%
Trailing 12-Months
Asset Growth
19.74%
Trailing 12-Months
Company Description
Mesoblast
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
MESO Company Deck
MESO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed strong commercial momentum following the successful Ryoncil launch (USD 49M H1 revenue, 93% gross margin), meaningful market access achievements (coverage for >280M lives, J-code, centers onboarded), robust cash and financing flexibility (USD 130M cash and new USD 125M facility), and compelling randomized data for Revascor and progress on rexlemestrocel-L. Offsetting these positives are sharp increases in R&D and SG&A as the company scales commercialization and advances clinical programs, continued operating losses and notable dependency on a single launched product while other programs mature. Overall, the call emphasized execution progress, regulatory engagement, and a clear path for near-term milestones, with manageable financial and execution risks.View all MESO earnings summariesMESO Stock 12 Month Forecast
Average Price Target
$35.00
▲(112.64% Upside)
Technical Analysis
Sarepta Therapeutics
―
Cogent Biosciences
―
Adaptive Biotechnologies
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Ownership Overview
26.26% Insiders
0.01% Mutual Funds
0.25% Other Institutional Investors
73.07% Public Companies and
Individual Investors